TCRX TScan Therapeutics, Inc.

NASDAQ
$0.34

TScan Therapeutics, Inc. (TCRX) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.26 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -57.0% since its last earnings release on August 12, 2026.

TScan Therapeutics, Inc. Beat Consensus Estimates
Wednesday, August 12, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.26)
Rev est $3M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.42

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.